Diamedica Therapeutics Stock Analysis

DMAC Stock  USD 2.92  0.08  2.82%   
The main objective of DiaMedica Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what DiaMedica Therapeutics is worth, separate from its market price. There are two main types of DiaMedica Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect DiaMedica Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of DiaMedica Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The DiaMedica Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. DiaMedica Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. DiaMedica Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and DiaMedica Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

DiaMedica Stock Analysis Notes

About 29.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.94. Some equities with similar Price to Book (P/B) outperform the market in the long run. DiaMedica Therapeutics recorded a loss per share of 0.6. The entity last dividend was issued on the 15th of November 2018. The firm had 1:20 split on the 15th of November 2018. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To learn more about DiaMedica Therapeutics call Dietrich MBA at 763 612 6755 or check out https://www.diamedica.com.

DiaMedica Therapeutics Quarterly Total Revenue


DiaMedica Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. DiaMedica Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding DiaMedica Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
DiaMedica Therapeutics generated a negative expected return over the last 90 days
DiaMedica Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (13.68 M) with profit before overhead, payroll, taxes, and interest of 0.
DiaMedica Therapeutics currently holds about 38.44 M in cash with (11.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45.
DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 29.0% of the company shares are held by company insiders
Latest headline from simplywall.st: Individual investors who hold 48 percent of DiaMedica Therapeutics Inc. gained 16, insiders profited as well

DiaMedica Therapeutics Upcoming and Recent Events

Earnings reports are used by DiaMedica Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to DiaMedica Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
26th of March 2024
Upcoming Quarterly Report
20th of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
26th of March 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

DiaMedica Largest EPS Surprises

Earnings surprises can significantly impact DiaMedica Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

DiaMedica Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. DiaMedica Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that DiaMedica Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial DiaMedica Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
13th of November 2023
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
5th of September 2023
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
14th of August 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
27th of June 2023
Unclassified Corporate Event
23rd of June 2023
Unclassified Corporate Event
21st of June 2023
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
30th of May 2023
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
22nd of May 2023
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure

DiaMedica Therapeutics Thematic Classifications

In addition to having DiaMedica Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

DiaMedica Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as DiaMedica Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DiaMedica Therapeutics backward and forwards among themselves. DiaMedica Therapeutics' institutional investor refers to the entity that pools money to purchase DiaMedica Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Morgan Stanley - Brokerage Accounts2023-06-30
57.1 K
Catalyst Financial Partners Llc2023-09-30
36.3 K
Bank Of New York Mellon Corp2023-09-30
34.6 K
Dimensional Fund Advisors, Inc.2023-06-30
17 K
Susquehanna International Group, Llp2023-06-30
16.9 K
Charles Schwab Investment Management Inc2023-06-30
13.3 K
Bnp Paribas Arbitrage, Sa2023-06-30
9.8 K
Citadel Advisors Llc2023-06-30
7.9 K
Tower Research Capital Llc2023-06-30
6.2 K
Cooperman Leon G2023-06-30
876 K
Vanguard Group Inc2023-06-30
783 K
Note, although DiaMedica Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

DiaMedica Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 107.79 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate DiaMedica Therapeutics's market, we take the total number of its shares issued and multiply it by DiaMedica Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

DiaMedica Profitablity

DiaMedica Therapeutics' profitability indicators refer to fundamental financial ratios that showcase DiaMedica Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, DiaMedica Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, DiaMedica Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of DiaMedica Therapeutics' profitability requires more research than a typical breakdown of DiaMedica Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2023
Return on Average Assets(0.36)(0.39)
Return on Average Equity(0.38)(0.41)
Return on Invested Capital(0.41)(0.42)
Return on Sales(10.18)(10.98)

Management Efficiency

DiaMedica Therapeutics has return on total asset (ROA) of (0.2547) % which means that it has lost $0.2547 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3962) %, meaning that it created substantial loss on money invested by shareholders. DiaMedica Therapeutics' management efficiency ratios could be used to measure how well DiaMedica Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 9, 2023, Return on Average Assets is expected to decline to -0.39. In addition to that, Return on Average Equity is expected to decline to -0.41. At present, DiaMedica Therapeutics' Tangible Assets Book Value per Share are projected to increase slightly based on the last few years of reporting.
Last ReportedProjected for 2023
Book Value per Share 1.20  1.31 
Enterprise Value over EBIT(3.00)(3.24)
Enterprise Value over EBITDA(2.91)(3.13)
Price to Book Value 1.31  1.35 
Tangible Assets Book Value per Share 1.30  1.44 
Enterprise Value39.5 M40.5 M
Tangible Asset Value34.4 M29.6 M
The analysis of DiaMedica Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze DiaMedica Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of DiaMedica Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.

Technical Drivers

As of the 9th of December, DiaMedica Therapeutics shows the Coefficient Of Variation of (2,962), standard deviation of 3.79, and Mean Deviation of 2.77. DiaMedica Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze thirteen technical drivers for DiaMedica Therapeutics, which can be compared to its rivals. Please confirm DiaMedica Therapeutics information ratio, potential upside, and the relationship between the standard deviation and maximum drawdown to decide if DiaMedica Therapeutics is priced favorably, providing market reflects its regular price of 2.92 per share. Please also check DiaMedica Therapeutics jensen alpha, which is currently at (0.18) to verify the company can sustain itself at a future point.

DiaMedica Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as DiaMedica Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

DiaMedica Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DiaMedica Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on DiaMedica Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DiaMedica Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

DiaMedica Therapeutics Technical and Predictive Indicators

DiaMedica Therapeutics Forecast Models

DiaMedica Therapeutics' time-series forecasting models are one of many DiaMedica Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary DiaMedica Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About DiaMedica Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how DiaMedica Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling DiaMedica shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as DiaMedica Therapeutics. By using and applying DiaMedica Stock analysis, traders can create a robust methodology for identifying DiaMedica entry and exit points for their positions.
Last ReportedProjected for 2023
EBITDA Margin(10.15)(10.95)
Gross Margin 0.90  0.89 
Profit Margin(10.32)(11.14)

Current DiaMedica Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. DiaMedica analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. DiaMedica analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.0Strong Buy1Odds
DiaMedica Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most DiaMedica analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand DiaMedica stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of DiaMedica Therapeutics, talking to its executives and customers, or listening to DiaMedica conference calls.
DiaMedica Analyst Advice Details

DiaMedica Stock Analysis Indicators

DiaMedica Therapeutics stock analysis indicators help investors evaluate how DiaMedica Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading DiaMedica Therapeutics shares will generate the highest return on investment. By understating and applying DiaMedica Therapeutics stock analysis, traders can identify DiaMedica Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow4.7 M
Total Stockholder Equity31.8 M
Net Borrowings-6000.00
Capital Lease Obligations469 K
Total Liab2.6 M
Property Plant And Equipment Net560 K
Cash And Short Term Investments33.5 M
Net Invested Capital31.8 M
Cash4.7 M
50 Day M A2.3791
Total Current Liabilities2.2 M
Investments11.5 M
Interest Expense353 K
Stock Based Compensation1.5 M
Common Stock Shares Outstanding26.4 M
Tax Provision28 K
Free Cash Flow-11.6 M
Other Current Assets251 K
Accounts Payable734 K
Net Debt-4.3 M
Depreciation25 K
Other Operating Expenses14 M
Non Current Assets Total560 K
Liabilities And Stockholders Equity34.4 M
Home CategoryDomestic
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for DiaMedica Stock analysis

When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.